Detalles de la búsqueda
1.
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Blood
; 142(16): 1348-1358, 2023 10 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37369099
2.
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Blood
; 135(24): 2137-2145, 2020 06 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32219442
3.
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
Br J Haematol
; 195(2): 201-209, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34341990
4.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33189178
5.
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Am J Hematol
; 96(9): 1120-1130, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34062004
6.
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Am J Hematol
; 96(6): 708-718, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33755235
7.
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Am J Hematol
; 95(4): 362-371, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31868245
8.
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.
Br J Haematol
; 185(3): 492-502, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30828799
9.
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
N Engl J Med
; 373(25): 2425-37, 2015 Dec 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-26639149
10.
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
Am J Hematol
; 93(11): 1402-1410, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30129285
11.
Oil Sands Derived Naphthenic Acids Are Oxidative Uncouplers and Impair Electron Transport in Isolated Mitochondria.
Environ Sci Technol
; 52(18): 10803-10811, 2018 09 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-30102860
12.
Mitochondrial transition ROS spike (mTRS) results from coordinated activities of complex I and nicotinamide nucleotide transhydrogenase.
Biochim Biophys Acta Bioenerg
; 1858(12): 955-965, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28866380
13.
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lancet
; 387(10027): 1551-1560, 2016 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26778538
14.
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
Am J Hematol
; 97(11): E416-E419, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36054316
15.
Bioenergetic and volume regulatory effects of mitoKATP channel modulators protect against hypoxia-reoxygenation-induced mitochondrial dysfunction.
J Exp Biol
; 219(Pt 17): 2743-51, 2016 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27358470
16.
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
Am J Hematol
; 96(10): E383-E386, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34161627
17.
Hypoxia-reoxygenation differentially alters the thermal sensitivity of complex I basal and maximal mitochondrial oxidative capacity.
Comp Biochem Physiol A Mol Integr Physiol
; 201: 87-94, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27387443
18.
A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Haematologica
; 105(4): e164-e168, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31413095
19.
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.
Br J Haematol
; 186(1): 184-188, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30740654
20.
Effects of hypoxia-cadmium interactions on rainbow trout (Oncorhynchus mykiss) mitochondrial bioenergetics: attenuation of hypoxia-induced proton leak by low doses of cadmium.
J Exp Biol
; 217(Pt 6): 831-40, 2014 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24265424